Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

t candidates, including having no unexpected safety, toxicology, clinical or other issues and having no unexpected clinical trial results such as unexpected new clinical data and unexpected additional analysis of existing clinical data; (ii) risks related to the regulatory process for the company's product candidates, including the possibility that the results of the new 52-week Phase 3 clinical trial (ASCEND) having an FVC endpoint may not be satisfactory to the FDA for InterMune to receive regulatory approval for pirfenidone in the United States; (iii) risks related to unexpected regulatory actions or delays or government regulation generally; (iv) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue; (v) government, industry and general public pricing pressures; (vi) risks related to our ability to successfully launch and commercialize Esbriet in Europe and Canada, including successfully establishing a commercial operation in Europe and Canada and receiving favorable governmental pricing and reimbursement approvals in the various European countries and securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans in Canada; and (vii) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections.  The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K, Form 10-Q and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.intermune.com.

Esbriet® is a registered trademark of InterMune, Inc.Financial tables follow:

 

 InterMune, Inc.PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERAT
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... MOUNTAIN VIEW, Calif. , Feb. 26, 2015 /PRNewswire/ ... appointment of Kate Black as Privacy Officer ... international, federal, and state privacy laws as well as ... and regulatory team, she will be responsible for reviewing, ... for customers in the U.S. and abroad. She joined ...
(Date:2/26/2015)... , Feb. 26, 2015   Regulus Therapeutics ... company leading the discovery and development of innovative medicines ... , Ph.D., President and Chief Executive Officer of Regulus, ... Company 35 th Annual Healthcare Conference on Wednesday, ... is being held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 The Movement ... demonstration to support life extension technologies and awareness. The ... Universal Coordinated Time, on March 21st 2015, in a ... , Eric Schulke, Founder of MILE, says, “Our ... with urgency. The Movement for Indefinite Life Extension is ...
(Date:2/26/2015)... The healthcare landscape is rapidly and radically changing. ... will host its 20 th Anniversary Medical Technologies ... to 10, at the Hilton San Diego Resort and Spa ... This event is a platform for global medical devices, diagnostics, ... and how to succeed in an uncertain future. ...
Breaking Biology Technology:23andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3
... years of cumulative expertise ... ... Tobira,Therapeutics Inc., a clinical stage biotechnology company committed to the,research and product ... company,s,senior management team. Tobira Therapeutics has been led since its,inception in 2006 ...
... Today at 1:00 pm ET / 10:00 am ... Anesiva,Inc. (Nasdaq: ANSV ) today announced ... (lidocaine hydrochloride monohydrate) powder,intradermal injection system. Zingo is ... associated with peripheral,intravenous (IV) line placements and blood ...
... June 30 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... with,Theragenex, LLC and its Chairman and President and ... the Company has received,in full. The parties have ... action and all related claims and counterclaims, with,prejudice. ...
Cached Biology Technology:Tobira Therapeutics Inc. Announces Senior Management Team 2Tobira Therapeutics Inc. Announces Senior Management Team 3Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 2Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 3Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 4Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children 5ADVENTRX Settles Dispute With Former Licensee 2
(Date:2/5/2015)... 26, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... http://www.nxt-id.com/ ) as part of its 2015 marketing and ... launched its new consumer website for Wocketwallet.com earlier this ... of NXT-ID said, "Our new corporate website naturally showcases ...
(Date:2/5/2015)... 28, 2015 Research and Markets ... the "Global Biometrics Market (2014-2020): Market Forecast ... report to their offering. , ... is anticipated to overtake ... increasing government spending towards IT security, government biometric ...
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... even those caused by antibiotic-sensitive bacteria, resist treatment. This ... impossible to cure. A key cause of this ... Starved bacteria resist killing by nearly every type of ... What produces starvation-induced antibiotic resistance, and how ...
... While shorter days and colder weather move many ... spent their summers in fieldwork are more likely to ... samples and crunching data from their summer,s labors. ... spent a month last summer in Mexico,s Sea of ...
... Although scientists have known for centuries that many bacteria produce ... toxic by-product of cellular activity. Now, researchers at NYU ... major role in protecting bacteria from the effects of numerous ... Nudler, PhD, the Julie Wilson Anderson Professor of Biochemistry at ...
Cached Biology News:What bacteria don't know can hurt them 2What bacteria don't know can hurt them 3Squid mystery in Mexican waters unraveled by Stanford biologist and a class of students 2Squid mystery in Mexican waters unraveled by Stanford biologist and a class of students 3Squid mystery in Mexican waters unraveled by Stanford biologist and a class of students 4Targeting bacterial gas defenses allow for increased efficacy of numerous antibiotics 2
... aptamer screening and binding optimization and built ... on-chip synthesis platform. These microarrays are available ... Microarray Service. Probe Content ... than 1500 known aptamer sequences. Add up ...
... provides a comprehensive service for custom ... peptide microarrays synthesized on Paraflo microfluidic ... proteins/antibodies or serum samples. This comprehensive ... designs, binding assays using sample(s) provided ...
... Sciences provides a comprehensive epitope analysis ... synthesized on Paraflo microfluidic chips for ... development. This comprehensive service includes assistance ... using sample(s) provided by you, single ...
... Microarrays designed for RNA aptamer screening ... flexible and powerful Paraflo microfluidic on-chip synthesis ... can be synthesized on-chip and LC Sciences ... These microarrays are available as part of ...
Biology Products: